---
layout: default
title: Sodium Chloride
parent: Low Evidence (L5)
nav_order: 910
evidence_level: L5
indication_count: 10
---

# Sodium Chloride
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sodium Chloride: From Intravenous Fluid and Electrolyte Products to Breast Fibrocystic Disease

## One-Sentence Summary

Sodium chloride is a basic electrolyte, marketed in Singapore mainly as saline infusion and injection products. The registration data does not record an approved indication.
The TxGNN model predicts it may be relevant to **breast fibrocystic disease**, but **no therapeutic evidence** supports this. There is **1 registered clinical trial** (a diagnostic imaging study that does not test sodium chloride) and **7 publications** (all describing cyst fluid composition or unrelated topics, none testing treatment).

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Breast fibrocystic disease |
| TxGNN Prediction Score | 96.79% |
| Evidence Level | L4 (mechanism and biochemical studies only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Sodium chloride is the main extracellular electrolyte, and its use as a fluid and electrolyte replacement is well established. No pharmacological mechanism links it to treating breast cysts.

The only link in the literature is compositional. Sodium and chloride are the main electrolytes in breast cyst fluid, and studies use the Na+/K+ ratio to classify cysts into types (for example PMID 2140797). This describes what cyst fluid contains. It does not show that sodium chloride treats the condition.

The high TxGNN score most likely reflects this co-occurrence in the knowledge graph rather than a therapeutic relationship. It should be treated as a hypothesis-generating signal only.

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT02887937](https://clinicaltrials.gov/study/NCT02887937) | N/A | Completed | 135 | Contrast-enhanced ultrasound to assess cystic breast masses and decide whether biopsy is needed. Diagnostic study; sodium chloride is not the intervention. |

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [2015669](https://pubmed.ncbi.nlm.nih.gov/2015669/) | 1991 | Biochemical analysis | Clinical Chemistry | Cyst fluid protein GCDFP-70 was identified as albumin and used to classify cysts into two types. |
| [2140797](https://pubmed.ncbi.nlm.nih.gov/2140797/) | 1990 | Biochemical/hormonal analysis | Eur J Surg Oncol | In 88 patients, cysts were classified by Na+/K+ ratio, chloride, glucose, pH and DHAS. Describes composition, not treatment. |
| [9375824](https://pubmed.ncbi.nlm.nih.gov/9375824/) | 1997 | Comparative fluid analysis | Nephron | Compared electrolytes and amino acids in breast cyst fluid and polycystic kidney cyst fluid. |
| [3369685](https://pubmed.ncbi.nlm.nih.gov/3369685/) | 1988 | Laboratory study | Anal Biochem | Fractionation method for type V collagen in dysplastic and carcinomatous breast tissue. Laboratory technique only. |
| [10797312](https://pubmed.ncbi.nlm.nih.gov/10797312/) | 2000 | In vitro cell study | J Cell Physiol | Intracellular pH regulation in nonmalignant and malignant breast cell lines. Not relevant to treatment. |
| [3232934](https://pubmed.ncbi.nlm.nih.gov/3232934/) | 1988 | Case series | Ann Plast Surg | Breast reconstruction in 98 patients using saline-inflatable implants. Saline is the implant filling, not a treatment. |
| [23073330](https://pubmed.ncbi.nlm.nih.gov/23073330/) | 2012 | Case report | Am J Surg Pathol | NK/T-cell lymphoma arising in association with a saline breast implant. Not relevant to efficacy. |

## Singapore Market Information

20 registrations in total. Five main authorizations are listed below.

| Authorization Number | Product Name | Dosage Form |
|---------|------|------|
| SIN05951P | Sodium Chloride Intravenous Infusion BP 0.9% | Injection |
| SIN16603P | Baxter-Sodium Chloride Injection USP 0.9% w/v | Infusion, solution |
| SIN09481P | Sodium Chloride Injection BP 0.9% | Injection |
| SIN06865P | Sodium Chloride Injection USP 0.45% | Injection |
| SIN09858P | Sodium Chloride Injection BP 0.9% w/v | Injection |

Other registered dosage forms include solution, sterile solution and enema.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No study tests sodium chloride as a treatment for breast fibrocystic disease. The linked literature describes cyst fluid composition only, and the single trial is a diagnostic imaging study. The prediction rests on the model score alone.

**To proceed, the following is needed:**
- A therapeutic or mechanistic rationale for sodium chloride in breast cysts, with at least one interventional study
- Mechanism of action (MOA) data
- HSA package insert warnings and contraindications, which are currently missing and block safety screening
- Route compatibility assessment, since the available Singapore forms are mainly intravenous
- Consider the lower-ranked prediction **vulvovaginitis** as a more promising direction. A clinical study of saline vaginal irrigation in infectious vaginitis (PMID 22301569) exists, but its design and outcome still need confirmation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

